Last reviewed · How we verify
BMS-986166
At a glance
| Generic name | BMS-986166 |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis (PHASE2)
- A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants (PHASE1)
- A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants (PHASE1)
- A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential (PHASE1)
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants (PHASE1)
- A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers (PHASE1)
- A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-986166 CI brief — competitive landscape report
- BMS-986166 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI